The ScyFIX 700 MCN Therapy is the only patented Micro Current Neuromodulation (MCN) device approved in Europe for the treatment of Retinitis Pigmentosa. Compelling Clinical Results: Retinitis Pigmentosa (RETINITIS PIGMENTOSA) and our Dry Age-Related Macular Degeneration (“ARMD”) are degenerative diseases, and improvement in visual fields, visual acuity, or contrast sensitivity is not expected. Data through twenty-four months suggests that MCN therapy is clinically effective. The data reflects that MCN therapy has not only slowed down the progression of disease symptoms as intended, but has in many cases halted, and in some cases reversed the progression of the diseases.
Patients are now using mobile phones, reading newspapers, seeing faces of family members and threading needles, none of these day to day activities were possible for these patients before using the ScyFIX MCN device. Similar compelling results have been achieved in our Dry Age-Related Macular Degeneration (“ARMD”) trial as well.